SPOTLIGHT -
Intravitreal implant could bring significant cost savings to NHS England
A study has revealed that a budgetary saving per treated patient with the fluocinolone acetonide implant (Iluvien) versus ranibizumab (Lucentis) could lead to a significant cost-saving to NHS England.
Read More
